24 Protein glycosylation is one of the most abundant post-translational modifications. However, 25 detailed analysis of in vivo O-linked glycosylation, a major type of protein glycosylation, has 26 been severely impeded by the scarcity of suitable methodologies. Here, we present a 27 chemoenzymatic method for the site-specific extraction of O-linked glycopeptides (EXoO), 28 which enabled the unambiguous mapping of over 3,000 O-linked glycosylation sites and 29 definition of their glycans on over 1,000 proteins in human kidney tissues, T cells and serum. 30 This large-scale localization of O-linked glycosylation sites nearly doubles the number of 31 previously identified sites, demonstrating that EXoO is the most effective method to-date for 32 defining the site-specific O-linked glycoproteome in different types of sample. Detailed 33 structural analysis of the sites identified revealed conserved motifs and topological orientations 34 facing extracellular space, the cell surface, the lumen of the ER and the Golgi. EXoO was also 35 able to reveal significant differences in the in vivo O-linked glycoproteome of tumor and normal 36 kidney tissues pointing to its broader use in clinical diagnostics and therapeutics. 37 38
including the use of lectins 6, 7 , HILIC 8, 9 , hydrazide chemistry 10, 11 , metabolic labelling 5, 12 and a 61 gene-engineered cell system named 'SimpleCell' 13 . However, all of these methodologies have 62 deficiencies that mean that the limited accessibility to the in vivo O-linked glycoproteome they 63 afford remains as a severe hindrance to the structural and functional study of in vivo O-linked 64 glycoproteins. In addition to the current difficulties in enrichment of O-linked glycopeptides 65 from complex mixtures, the precise pinpointing of O-linked glycosylation sites and their 66 corresponding site-specific glycans has proved to be even more challenging. Mass spectrometry 67 (MS) using electron transfer dissociation (ETD) for fragmentation has to-date been the prevailing 68 analytical tool to localize O-linked glycosylation sites 14 . Caveats associated with site localization 69 using ETD render the method to be inefficient in mapping sites 15, 16 . Alternatively, chemical 70 deglycosylation such as β-elimination Michael addition can be used to substitute O-linked 71 glycans for glycosylation site identification 17 . However, a variety of complications and non-72 specific substitutions at other posttranslational modifications or at unmodified Ser and Thr limits 73 the performance of this alternative method when employed on complex samples 17 . In sharp 74 contrast, the identification of N-linked glycosylation sites and N-linked glycans is highly 75 efficient making use of a specific enzyme (PNGase F) and the consensus NXS/T motif (X ≠ 76 Pro) 18 . PNGase F simultaneously liberates N-linked glycans and converts the Asn in the 77 glycosylation site to Asp (deamination) thereby identifying the site 19, 20 
T cells and serum 122
EXoO was benchmarked using human kidney tissue, T cells and serum to determine 123 performance of the method in samples with differing levels of protein complexity. To do this, O-124 linked glycopeptides were extracted using EXoO and fractionated into 24 fractions and then 125 subjected to LC-MS/MS analysis ( Fig. 2A ). To study kidney tissue, paired tumor and normal 126 tissues were collected from three patients. The extracted proteins from these tissues were 127 separately pooled to generate two samples i.e. tumor and normal. After analysis with 1% false 128 discovery rate (FDR) at PSM level, 35,848 PSMs were assigned to 2,804 O-linked glycopeptides 129 containing 1,781 O-linked glycosylation sites from 590 glycoproteins ( Supplementary Table 2 ). 130
When the EXoO approach was applied to the analysis of T cells, 4,623 PSMs were assigned to 131 contain 1,295 O-linked glycosylation sites from 1,982 O-linked glycopeptides and 590 132 glycoproteins ( Supplementary Table 3 ). Finally, human serum that contains a number of highly 133 glycosylated proteins and has been previous subjected to detailed mapping of N-linked 134 glycosylation sites and N-linked glycans but for which there has been little success in mapping 135 of O-linked glycosylation sites and O-linked glycans [21] [22] [23] [24] [25] To determine sample-specific O-linked glycoproteome, the distribution of EXoO identified 150 peptides in different samples was determined. Kidney tissue and T cells had a large number of 151 unique peptides compared to that seen for serum, with more than half of peptides detected in 152 serum also being identified in the tissue sample, possibly due to the presence of serum in tissue 153 samples ( Fig. 2B ). To visualize the relative abundance of peptides in different samples, the PSM 154 numbers of peptides, which are suggestive of relative abundance, were clustered by unsupervised 155 hierarchical clustering ( Fig 2C) . This showed that not only that the peptides differed between 156 samples but also that their relative abundances were markedly divergent between samples ( Fig O-linked glycosylation sites ( Supplementary Fig. 2 ). Thirteen O-linked glycosylation sites were 172 not used in the motif analysis because they were located close to the termini of proteins 173 concerned and consequently did not have enough surrounding amino acids to allow for full motif 174
analysis. 175
Gene ontology (GO) analysis of EXoO identified glycoproteins was carried out and this showed 176 that extracellular space, the cell surface, the ER lumen and the Golgi membrane were the major 177 To determine localization of the sites to protein structures, protein topological and structural 203 annotations were retrieved from Uniprot database and mapped to the EXoO identified sites. It 204 was found that approximately 28.3 and 10.3% of the sites were predicted to localize in 205 extracellular and luminal region, respectively ( Supplementary Fig. 4 ). In contrast, only 206 approximately 1.6% of the sites were predicted in cytoplasmic compartment ( Supplementary Fig.  207   4) . Approximately 5% of the sites were associated with Ser/Thr/Pro-rich region but weaker 208 correlation of the sites to other protein structures including repeats, coiled coil, beta strand, helix, 209 turn and signal peptides ( Supplementary Fig. 4 ). Close to none correlation of the sites to intra- To identify changes in the O-linked glycoproteome between normal and tumor kidney tissue, 217 spectral counting label-free quantification of the EXoO identified peptides was used ( Fig. 3A) . 218
This identified 56 O-linked glycoproteins as exhibiting significant change using scoring criteria 219 of at least a two-fold change together with a difference of at least 10 PSMs between normal and 220 tumor samples ( Fig. 3A, Supplementary table 6 ). The most striking change observed was the 221 dramatic increase of O-linked glycans, primarily in the core 1 structure Hex(1)HexNAc(1) across 222 the 163 and 82 sites mapped in VCAN and ACAN respectively ( ADAMTS7, SERPINE1, ANPEP, PAPLN, ADAMTSL5, GGT5 and CPXM1 detected in tumor 238 tissue ( Fig. 3D and Supplementary table 6 ). This type of fine-tuning of the ECM network is 239 known to be critical to supporting tumorigenesis and tumor progression 31 . In addition, carbonic 240 anhydrase 9 (CA9) and angiopoietin-related protein 4 (ANGPTL4), proteins known to respond to 241 tumor hypoxia 32, 33 , showed 13 and 3.6-fold increases respectively in tumor tissue ( Fig. 3D and 242 Supplementary table 6 ). Finally, EGF-containing fibulin-like extracellular matrix protein 1 243 (EFEMP1) which binds to epidermal growth factor receptor (EGFR) to promote tumor growth, 244 invasion and metastasis 34 , showed a 3-fold increase across seven O-linked glycosylation sites in 245 tumor tissue ( Fig. 3D and Supplementary table 6 
Solid-phase extraction of site-specific O-linked glycopeptides from fetuin 287
Bovine fetuin (P12763) were denatured in buffer containing 8 M urea and 1 M ammonium 288 bicarbonate (AB) and reduced in 5 mM DTT at 37°C for 1 hour. Proteins were alkylated in 10 289 mM iodoacetamide at room temperature (RT) for 40 min in the dark. The resulting samples were 290 diluted eight-fold using 100 mM AB buffer before adding trypsin (enzyme/protein ratio of 1/40 291 w/w) and incubating at 37C for 16 hours. Following digestion, peptides were de-salted using a 292 C18 column (Waters, Milford, MA) according to manufacturer's instructions. 293
Peptides were conjugated to AminoLink resin (Pierce, Rockford, IL) as previously described 20 . 294
Briefly, the pH of the peptide containing eluate of the C18 column was adjusted to 7.4 by adding 295 phosphate buffer (pH 8.0). Peptides were then incubated with the resin (100 µg/100 µl resin, 296 50% slurry) and 50 mM sodium cyanoborohydride (NaCNBH 3 ) at RT for at least 4 hours or Tris-HCl buffer (pH 7.4) to collect the remaining peptides. The pooled peptides were then 305 desalted on a C18 column and dried by lyophilization. 306
Extraction of O-linked glycopeptides from human kidney tissue, serum and T cells 307
Collection and use of human tissue has been approved by Johns Hopkins Institutional Review 308 Board (IRB). Kidney tumors were categorised as being clear cell renal cell carcinomas (CCRCC) 309 and samples of tumor tissue were stored at -80°C before use. Control ormal kidney tissue 310 samples were collected from the same individuals. Proteins from human kidney tissues, serum 311 (Sigma-Aldrich, St. Louis, MO) and CEM T cells were trypsin-digested as described above. 312
Following digestion, guanidination of peptides was conducted on a C18 column using procedure 313 described previously to recover the Lys-containing peptides from complex samples 17 . Briefly, 314 peptides were loaded on a pre-conditioned C18 column. The column was then sequentially 315 washed three times with 0.1% TFA and then guanidination solution (equal volumes of 2.85 M 316 aqueous ammonia, 0.6 M O-methylisourea and 0.1% TFA, final pH 10.5). After the final wash, 317 guanidination solution was added to cover the C18 material in the column and it was incubated at 318 65°C for 20 min. Following this incubation, the column was cooled to RT and washed three time 319 with 0.1% TFA. Peptides were eluted in 60% acetonitrile/0.1% TFA. Intact glycopeptides were 320 enriched using a SAX HyperSep TM Retain AX Columns (RAX) column 9 . Briefly, after C18 321 desalting peptides in 60% acetonitrile/0.1% TFA were adjusted to 95% acetonitrile/1% TFA. The 322 RAX column was conditioned in acetonitrile, 100 mM triethylammonium acetate, water and 323 finally 95% acetonitrile/1% TFA using three times per solution. Samples were loaded, washed 324 three times using 95% acetonitrile/1% TFA and eluted in 50% acetonitrile/0.1% TFA. The 325 samples were then dried by lyophilization. 326
Peptide fractionation 327
Peptides (100 µg) were split into 96 fractions using a 1220 Series HPLC (Agilent Technologies, 328
Inc., CA) equipped with a Zorbax Extend-C18 analytical column containing 1.8 μm particles at a 329 flow rate of 0.3 ml/min. The mobile-phase A was 10 mM ammonium formate (pH 10) and B was 330 10 mM ammonium formate and 90% acetonitrile (pH10). Peptides were separated using the 331 following linear gradient: 0-2% B, 10 min; 2-8% B, 5 min; 8-35% B, 85 min; 35-95% B, 5 332 min; 95-95% B, 15 min. Fractions were collected from 0 to 96 min. The 96 fractions were 333 concatenated into 24 fractions. The samples were then dried by lyophilization. 334
LC-MS/MS analysis 335
Peptides dissolved in 0.1% formic acid (FA) were analyzed on a Fusion Lumos mass 336 spectrometer with an EASY-nLC 1200 system or a Q-Exactive HF mass spectrometer (Thermo 337
Fisher Scientific, Bremen, Germany) with a Waters NanoAcquity UPLC (Waters, Milford, MA). 338
The mobile phase flow rate was 0.2 μL/min with 0.1% FA/3% acetonitrile in water (A) and 0.1% 339 FA/90% acetonitrile (B). The gradient profile was set as follows: 6% B for 1 min, 6−30% B for 340 84 min, 30−60% B for 9 min, 60−90% B for 1 min, 90% B for 5 min and equilibrated in 50% B, 341 flow rate was 0.5 μL/min for 10 min. MS analysis was performed using a spray voltage of 1.8 342 kV. Spectra (AGC target 4 × 10 5 and maximum injection time 50 ms) were collected from 350 to 343 1800 m/z at a resolution of 60 K followed by data-dependent HCD MS/MS (at a resolution of 50 344 K, collision energy 29, intensity threshold of 2 × 10 5 and maximum IT 250 ms) of the 15 most 345 abundant ions using an isolation window of 0.7 m/z. Charge-state screening was enabled to reject 346 unassigned, single, and more than six protonated ions. Fixed first mass was 110 m/z. A dynamic 347 exclusion time of 45s was used to discriminate against previously selected ions. 348
Database search of site-specific O-linked glycopeptides 349
Bovine fetuin (P12763) in a database with HIV gp120 (AAB50262.1) and TGFbeta1 (P01137) 350
were used for the analysis of fetuin using the same procedure for search of the human protein Static modification was carbamidomethylation (C). FDR set at 1% using Percolator. MS/MS 363 scan numbers of oxonium ion containing spectra were extracted with 10 ppm tolerance from raw 364 files. Oxonium ion 204 was mandatory together with two of the other oxonium ions. The result 365 was filtered to report identification with glycan modification and oxonium ions in the MS/MS 366 spectra. Percolator generated FDR was verified using peptide identification labelled with decoy-367 pro in the output result. 368
Label-free quantification using spectral counting 369
PSM numbers with 1% FDR were counted for peptides identified from tumor or normal tissue. 
